Internationale Partnersuche

Innovation & Technologie Angebot

Anti-CD3 used in immuno-suppressive drugs for the treatment of leukaemia, offered to oncology researchers via licencing agreement

Country of Origin: United Kingdom
Reference Number: TOUK20201216001
Publication Date: 6 January 2021

Summary

A UK non-profit organisation is providing access to Anti-CD3 (Anti-Cluster of Differentiation) from its original source Cancer Research UK, to academia and life science industry. The Anti-CD3 antibody is used as a pan T-cell marker in the detection of T-cell populations and in immuno-suppressive drugs for the treatment of leukaemia and is offered to cancer researchers and scientists in academia and industry, via licensing agreement.

Description

A UK non-profit organisation is providing access to Anti-CD3 from its original source Cancer Research UK, to academia and life science industry. 



This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with Anti-CD3 being one of the first successful fusions. It is available for researchers studying leukaemia, lymphocytes or the role of CD3 in T cell antigen receptor (TCR) signal transduction events.



The UK company has been commercialising life science research tools created by scientists working in cancer research for more than 25 years and provide a service making a range of antibodies and markers more readily available worldwide, including Anti-CD3, which is available for researchers and companies working in oncology, immunology and more via licensing agreement.

Advantages and Innovations

This UK non-profit organisation has both monoclonal and recombinant rights to Anti-CD3.



Since it was developed by Prof. Peter Beverley, over 20 research publications have been published using Anti-CD3 in application areas including oncology, immunology, stem cell biology, and cell signalling.

Stage Of Development

Already on the market

Requested partner

Type: Industry or academia

Activity of partner: Life science research in leukaemia, lymphocytes or the role of CD3

Specific role of partner sought: Licensing of the Anti-CD3 marker to contribute to their research and development

Kooperationsanfrage stellen